In June 2008, Nventa announced the development of a proprietary vaccine adjuvant, Poly IC – Poly Arginine (Poly-ICR), for use with both therapeutic and prophylactic vaccines.
•
Nventa is developing HspE7 in combination with the Toll-like receptor 3 (TLR3) agonist adjuvant Poly-ICLC for multiple indications, including Cervical Intraepithelial Neoplasia (also known as cervical dysplasia or CIN), Genital Warts, Cervical Cancer, and head and neck cancers.
Canadian Broadcasting Corporation | Australian Broadcasting Corporation | Oracle Corporation | International Finance Corporation | Chevron Corporation | Digital Equipment Corporation | News Corporation | Lockheed Corporation | corporation | Hearst Corporation | Scholastic Corporation | Northrop Corporation | Munhwa Broadcasting Corporation | Gibson Guitar Corporation | CBS Corporation | Fender Musical Instruments Corporation | ITT Corporation | Sharp Corporation | RAND Corporation | NCR Corporation | Federal Deposit Insurance Corporation | Sperry Corporation | Singer Corporation | Case Corporation | Science Applications International Corporation | Polaroid Corporation | Multinational corporation | Burroughs Corporation | Bendix Corporation | Olympus Corporation |